Journal of Medical Economics

Prostate cancer progression: a scoping review, pharmacoeconomic assessment, and evaluation of quality of life Prostate cancer is the most common malignancy in men and a leading cause of cancer-related death. Progression from non-metastatic castration-resistant prostate cancer (nmCRPC) to metastatic CRPC (m...

📣 Explore our latest review examining the impact of avoiding or delaying progression to 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐜𝐚𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧-𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐭 𝐩𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 on health-related quality of life, mortality, and economic outcomes.

Click the link to read the article in full 👉 bit.ly/49FgyIe

#prostatecancer #healtheconomics

𝐍𝐞𝐰 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Our latest article forecasts the #burden and #healthcarecosts of obesity in the US from 2023 to 2060. It also identifies strategic intervention windows for obesity treatments to maximise cost savings.

Click the link to read the full article 👉 bit.ly/48TDwuR

#HEOR #Healtheconomics

Our latest article examines 𝐈𝐜𝐨𝐝𝐞𝐜's cost-effectiveness compared to other long-acting insulins, including glargine, detemir, and degludec. Discover the authors' findings by clicking the link 👉 bit.ly/4higT5r

#diabetes #bloodsugar #costeffectiveness #healtheconomics #HEOR

New research in the Journal of Medical Economics: Assessment of unmet clinical needs and healthcare resource use among statin-treated patients with or at risk of developing atherosclerotic cardiovascular disease

A new analysis in @jme-journal.bsky.social identifies a costly gap in heart health. A majority of Americans with hypercholesterolemia are on statins, but most don't hit their LDL-C targets. Getting to goal was associated with a 50% reduction in cardiovascular events. bit.ly/48xvWWf

Use of patient-reported outcome measures in cost-effectiveness models informing health technology assessments of non-oncology treatments: a review Including patient-reported outcome measures (PROMs) in cost-effectiveness models (CEMs) represents an important opportunity to reflect patients’ perspectives in health technology assessments (HTAs)...

🚨 Available now🚨

Our latest review provides an essential insight into how #patientreportedoutcomemeasures can be included in #costeffectiveness models that inform #healthtechnologyassessments of non-oncology treatments.

Read it here 👉 www.tandfonline.com/doi/full/10....

Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs To assess use of external evidence for overall survival (OS) estimation in oncology single-technology appraisals (STAs) by the National Institute for Health and Care Excellence (NICE).STAs for onco...

🚨 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐞𝐝 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 🚨

Discover how Audrey Petitjean et al. assessed the use of external evidence for overall survival estimation in #oncology single-technology appraisals by the National Institute for Health and Care Excellence.

Click the link for the full article 👉 bit.ly/4glH9ey

#NICE #HEOR

Lost earnings among triptan non-responders in the general population of Denmark: a measure of disproportionate migraine-attributed burden and of unrecognised and unmet treatment need Migraine leads to substantial healthcare utilization and associated costs. However, much higher costs are attributed to lost productivity. The impact of effective migraine treatment on these costs,...

📢 𝑹𝒆𝒄𝒐𝒎𝒎𝒆𝒏𝒅𝒆𝒅 𝒓𝒆𝒂𝒅

Discover the impact of treatment failure for #migraine on lost earnings among #triptan non-responders in the general population of #Denmark. Click the link for the full article 👉 bit.ly/4piFVoy

@perspectumltd.bsky.social

🚨 𝐍𝐨𝐰 𝐨𝐧𝐥𝐢𝐧𝐞 🚨

Our latest article evaluates the budgetary impact of pathways using cT1 versus SoC (liver biopsy or VCTE) to assign suspected #MASH patients to #resmetirom. See the graphical abstract below for an overview of the study.

Click the link for the full article 👉 bit.ly/4g3dLJQ

Cost-effectiveness analysis of seasonal influenza vaccination compared to no vaccination in the United Arab Emirates and Iraq Influenza is often considered a trivial illness due to its generally mild symptoms. This perception overlooks the extensive scale of people affected annually, many of whom experience severe complic...

📢 𝑱𝒖𝒔𝒕 𝒑𝒖𝒃𝒍𝒊𝒔𝒉𝒆𝒅: Our latest article assesses the economic impact of #influenzavaccination across the #UAE and #Iraq. Click the link to access it in full 👇

bit.ly/3K2tz3u

Congratulations to the authors—it was lovely to collaborate with you.

#publichealth #costeffectiveness #HEOR

📢 𝐑𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐞𝐝 𝐫𝐞𝐚𝐝𝐢𝐧𝐠

" #Costeffectiveness of wastewater and environmental monitoring of #respiratorysyncytialvirus to guide universal infant immunoprophylaxis in #Canada"

Click the link to access the article in full or read the plain language summary below 👉 bit.ly/45BQlb3

#HEOR #Healtheconomics

We're excited to announce that our website now features a dedicated multimedia section showcasing our #videoabstracts. Access this content here👉 bit.ly/4oJik05

We have also expanded the extenders we offer to include #audioabstracts, #podcasts, and #videoarticles. Get in touch to find out more.

The Complete Publication Journey: Insights into strategic planning, submission guidelines and research reach - Author Services Preparing a publication plan for your manuscript is extremely beneficial, helping with maximizing the impact of your research further down the publication pipeline.

📣Available now

View our webinar which provides an essential insight into the #submission and #peerreview processes, such as best practices for what should be included in your manuscript.

👉 bit.ly/40XWFaa

#publishing #AI

Health economics in cancer treatment and care Explore the article collection: Health economics in cancer treatment and care. Published in Journal of Medical Economics.

We are currently commissioning articles for an article collection titled "Health Economics in #Cancer Treatment and Care" If you're interested in submitting, get in touch 👉 mike.gregg@tandf.co.uk
So far, four articles have been published in the collection — you can access them here.👉 bit.ly/4167G9h

Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment This study was performed to evaluate patients’ and physicians’ preferences regarding hepatitis C virus (HCV) treatment in Japan, particularly focusing on direct-acting antivirals. Understanding the...

🚨 𝐑𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐞𝐝 𝐫𝐞𝐚𝐝🚨

Discover the preference of patients and physicians for treatments of Hepatitis C infections in Japan in this article. Click the link for the full article 👉 bit.ly/46e4njD

#patientpreference #physicianpreference #hepatitisC #HEOR

🚨𝐖𝐞 𝐧𝐞𝐞𝐝 𝐲𝐨𝐮𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬🚨

What will shape #pharmacoeconomics in 2026? Your expert opinion matters! Take our quick survey, share your perspective, and be in for a chance to win a $40 Amazon gift voucher.

Click here for the survey 👉 bit.ly/3ZAiPP8

#HEOR #healtheconomics #medicaleconomics

📢 Your expert opinion on #pharmacoeconomics trends for 2026 matters! Complete our short survey to share your views, and be in for a chance to win a $40 Amazon gift voucher.

Click the link to have your say 👉 bit.ly/3ZAiPP8

#HEOR #healtheconomics #medicaleconomics

Complete our Survey Click Here

Looking ahead to 2026: Which #pharmacoeconomic topics will have the most impact? Share your expertise in this important discussion by completing our brief survey 👉 invt.io/1bxbq6unbf0

The results will be shared in an upcoming article in Taylor & Francis's health economics journals.

#HEOR

Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs To assess use of external evidence for overall survival (OS) estimation in oncology single-technology appraisals (STAs) by the National Institute for Health and Care Excellence (NICE).STAs for onco...

🚨New Article🚨

Read our latest article titled "Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs".

Click to view the article in full 👉 bit.ly/452YBB1

#HEOR #Healtheconomics #Pharmacoeconomics #NICE #technologyappraisals

Excited to be attending ISPOR Annual in Montreal, reach out if you are attending too and would like to connect!

#ispor2025 #ispor #heor #healtheconomics #outcomesresearch
#healthpolicy #medicaleconomics #pharmacoeconomics

Taylor & Francis celebrates 15 years of unique scheme supporting researchers in resource-constrained countries STAR (Special Terms for Authors and Researchers) gives individual unaffiliated researchers in over 100 countries free access to journal articles.

#Taylor&Francis commemorates 15 years of 𝗦𝗧𝗔𝗥 (𝗦𝗽𝗲𝗰𝗶𝗮𝗹 𝗧𝗲𝗿𝗺𝘀 𝗳𝗼𝗿 𝗔𝘂𝘁𝗵𝗼𝗿𝘀 𝗮𝗻𝗱 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀), an initiative aiding independent researchers without institutional affiliations. STAR grants access to cutting-edge research, bridging the gap for scholars worldwide.
Learn more👉 bit.ly/4jx3Htl
#publishing

Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin Evaluate existing oncology value frameworks in terms of their methodology, structure, characteristics, and functionality using the example of enfortumab vedotin, an approved therapy for urothelial ...

📢 Exciting opportunity for researchers! 📢

Adding a #graphicalabstract to your article captures a greater audience and increases views. See an excellent example below, to read the article in full, click here 👇
bit.ly/42EeQ5O

Want tips on how to make them? Get in touch 👇
mike.gregg@tandf.co.uk

Associations between procedural volume, costs, and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy in US hospitals We assessed the relationship between hospital septal reduction therapy (SRT) procedural volume and clinical outcomes, healthcare resource utilization, and hospital costs.This cross-sectional study ...

🚨New article alert🚨

Our latest article looks at the associations between procedural volume, costs, and outcomes of septal reduction therapies for #obstructivehypertrophiccardiomyopathy in US hospitals. To read it in full, click the link 👉 bit.ly/42wHFkA

#HEOR #healtheconomics #Cardiovascularhealth

🚨Journal news🚨

We are delighted to announce that Ishveen Chopra has joined our #EarlyCareerPanel. Ishveen is a seasoned leader in #HEOR, with a distinctive background spanning clinical, translational, and analytical research.

We are excited to work with Ishveen to support her career.

Systematic review of cost-effectiveness modelling studies for haemophilia Haemophilia is a rare genetic disease that hinders blood clotting. We aimed to review model-based cost-effectiveness analyses (CEAs) of haemophilia treatments, describe the sources of clinical evid...

🚨Available now!🚨

Read our latest article that analyzes the cost-effectiveness of various treatments for #haemophilia. Click the link for the full article 👉 bit.ly/3FN2GPb

#costeffectiveness #HEOR #healtheconomics #pharmacoeconomics

2024 in review: high impact articles from the Journal of Medical Economics Published in Journal of Medical Economics (Vol. 28, No. 1, 2025)

Take a deep dive into what articles our readers viewed most last year and discover the Editor in Chief's recommended reads, which he selected based on their innovation and impact.

Read the article in full here 👉 bit.ly/4c4oXnD

#HEOR #Healtheconomics #pharmacoeconomics #medicaleconomics

How to write and publish a Plain Language Summary | Learn why you should create a Plain Language Summary (PLS), the different types, and how to write and develop your PLS for publication.

Interested in how #plainlanguagesummaries can benefit your articles?

Discover this and a lot more in our "𝐡𝐨𝐰 𝐭𝐨 𝐰𝐫𝐢𝐭𝐞 𝐚 𝐩𝐥𝐚𝐢𝐧 𝐥𝐚𝐧𝐠𝐮𝐚𝐠𝐞 𝐬𝐮𝐦𝐦𝐚𝐫𝐲" guide, available here 👉 bit.ly/3tUaWkX

#PLS #laysummary #Taylor&Francis #healtheconomics #HEOR

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight o...

🚨Available now🚨

Discover the cost-effectiveness of #semaglutide in people with #obesity and #cardiovasculardisease without #diabetes in this latest article in the Journal of Medical Economics

Click the link for the full article 👉 bit.ly/4c7JlEn

#costeffectiveness #HEOR #pharmacoeconomics

Assessing the economic impact and healthcare resource utilization of inpatient pneumococcal disease among adults: a French national claims database study Pneumococcal diseases (PD) caused by Streptococcus pneumoniae include invasive PD (IPD) and non-bacteremia pneumococcal pneumonia (NBPP). Current French vaccination guidelines focus on patients wit...

🚨Now online🚨

An incredibly insightful original research article published last week in the Journal of Medical Economics, to access it in full click here 👉 bit.ly/4iB3XHc

Big thanks to the authors for publishing in JME.

Video Abstract - Comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2422227 © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Using #videoabstracts to discuss and summarise the findings of a paper is increasing in popularity for our authors. Below is a fantastic example, if you want to learn how to make them get in touch 👉 mike.gregg@tandf.co.uk

To view the paper in full click here👉 bit.ly/4ihgK1O
vimeo.com/1036790510